Changmao Bio projects H1 2026 net loss to narrow to RMB4–6 million, vs. RMB25.79 million a year earlier

Bulletin Express
Aug 03

Changmao Biochemical Engineering Company Limited said it expects to report a consolidated net loss attributable to shareholders of between RMB4 million and RMB6 million for the six months ended 30 June 2026. The projected figure marks a sharp improvement from the RMB25.79 million loss recorded in the same period of 2025.

Management attributed the reduced loss to two main factors: 1. Optimised product mix and expanded production capacity in response to market demand, which lifted both revenue and gross profit. 2. Progressive market expansion for products from the phase-II production line of subsidiary Changmao (Dalian) New Material Company Limited, helping to narrow net losses at that unit.

The figures are based on the Group’s unaudited management accounts; full interim results are scheduled for release on 18 August 2026. The company advised shareholders and potential investors to exercise caution when dealing in its shares.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10